Showing results (101-110 of 325) with videos related to
Sort By:
Pageof 33
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applicationsS Ahmad, A Ahsan, M George, et al.Thrombosis Research|November 15, 1997
Efficacy of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.International Angiology : a Journal of the International Union of Angiology|July 25, 2000
Pharmacokinetics of argatroban in primates: evidence on endogenous uptakeS Ahmad, L H Yang, A Ahsan, et al.The Canadian Journal of Cardiology|June 1, 1995
Successful treatment of heparin-associated thrombocytopenia and thrombosis using HirulogJ R Chamberlin, B Lewis, F Leya, et al.International Journal of Clinical Practice|June 30, 2010
Drug and dietary interactions of the new and emerging oral anticoagulantsJ M Walenga, C AdiguzelThrombosis Research|November 26, 1999
Laboratory monitoring of pentasaccharide in a dog model of hemodialysisD A Hoppensteadt, W P Jeske, J M Walenga, et al.Seminars in Thrombosis and Hemostasis|June 5, 1999
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulationJ Fareed, J M Walenga, D A Hoppensteadt, et al.Acta Chirurgica Scandinavica. Supplementum|January 1, 1990
Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effectsJ Fareed, J M Walenga, M Lassen, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodiesS Ahmad, W P Jeske, J M Walenga, et al.Pageof 33